Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

Hemophilia research, prevention, surveillance and service programs and issues H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (H.R. 3884/S. 1852)

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicaid program reforms, including telemedicine and prior authorization issues Section 340B Drug Pricing program, including H.R. 5378 (Lower Costs, More Transparency Act), Section 202 Drug pricing reforms generally Juvenile mental and behavioral health legislation generally "Food as medicine" nutrition programs generally H.R. 3884 and S. 1852 (Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023), all provisions H.R. 3391 (Gabriella Miller Kids First Research Act 2.0), all provisions H.R. 3887 (Children's Hospital GME Support Reauthorization Act of2023), all provisions Medicare "site neutral" payment policy generally, including H.R. 5378 (Lower Costs, More Transparency Act), Section 203 Pediatric cancer research generally Pediatric access to cell and gene therapies generally H.R. 4758 (Accelerating Kids' Access to Care Act), all provisions H.R. 7213 (Autism Collaboration, Accountability, Research, Education, and Support Act of2024), all provisions H.R. 8260 and S. 4350 (Hospital Inpatient Services Modernization Act), all provisions H.R. I 0545 (American Relief Act, 2025), regarding HHS program funding and Medicaid program reform provisions National Institutes of Health program reforms generally S. 904 (Sickle Cell Disease Comprehensive Care Act), all provisions

Client expense: $190,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423/H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039/H.R. 6301) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages Sickle cell disease quality measures House discussion draft of Stop Drug Shortages Act Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297) Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746) Sickle Cell Disease Treatment Centers Act (H.R. 9872/S. 5226) Sickle Cell Disease Comprehensive Care Act (H.R. 7432/S. 5097) FDA guidance impacting hematology

Client expense: $30,000 · Firm income: Not reported

Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423/H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039/H.R. 6301) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages Sickle cell disease quality measures House discussion draft of Stop Drug Shortages Act Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297) Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746) Sickle Cell Disease Treatment Centers Act (H.R. 9872/S. 5226) Sickle Cell Disease Comprehensive Care Act (H.R. 7432/S. 5097)

Client expense: $30,000 · Firm income: Not reported

H.R.7384/S.4583, the Creating Hope Reauthorization Act of 2024 H.Res.1307 - Expressing support for the designation of June 20, 2024, as "World FSHD Day". H.R. 7432, Sickle Cell Disease Comprehensive Care Act S. 1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 H.R. 5539, ORPHAN Cures Act H.R. 4408/S.1644, Promising Pathway Act S.4426,Promising Pathway Act 2.0 H.R. 3100, Sickle Cell Care Expansion Act of 2023

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicaid program reforms, including telemedicine and prior authorization issues Section 340B Drug Pricing program, including H.R. 5378 (Lower Costs, More Transparency Act), Section 202 Drug pricing reforms generally Juvenile mental and behavioral health legislation generally "Food as medicine" nutrition programs generally Advanced Research Projects Agency-Health program generally H.R. 3884 and S. 1852 (Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023), all provisions H.R. 3391 (Gabriella Miller Kids First Research Act 2.0), all provisions H.R. 3887 (Childrens Hospital GME Support Reauthorization Act of 2023), all provisions Medicare "site neutral" payment policy generally, including H.R. 5378 (Lower Costs, More Transparency Act), Section 203 Pediatric cancer research generally Pediatric access to cell and gene therapies generally H.R. 4758 (Accelerating Kids Access to Care Act), all provisions H.R. 7213 (Autism Collaboration, Accountability, Research, Education, and Support Act of 2024), all provisions H.R. 8260 and S. 4350 (Hospital Inpatient Services Modernization Act), all provisions

Client expense: Not reported · Firm income: $50,000

Medicaid program reforms, including telemedicine Section 340B Drug Pricing Program, including H.R. 5378 (Lower Costs, More Transparency Act), Section 202 Sickle cell disease research funding generally Drug pricing reforms generally Mental and behavioral health legislation generally Advanced Research Projects Agency-Health program generally H.R. 3887 (Childrens Hospital GME Support Reauthorization Act of 2023), all provisions H.R. 3884 and S. 1852 (Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023), all provisions Site neutral payments to providers generally, including H.R. 5378 (Lower Costs, More Transparency Act), Section 203 H.R. 6960 and S. 3765 (Emergency Medical Services for Children (EMSC) Reauthorization Act of 2024), all provisions H.R. 4758 (Accelerating Kids Access to Care Act), all provisions H.R. 7213 (Autism Collaboration, Accountability, Research, Education, and Support Act of 2024), all provisions Federal policies regarding Lab-Developed Tests, generally

Client expense: Not reported · Firm income: $50,000

Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 (H.R. 3884/S. 1852) Sickle Cell Disease Treatment Centers Act (H.R. 9872/S. 5226) Policies related to the social security disability programs; submitted nominees for NASEM sickle cell disease expert panel House and Senate Resolutions Expressing support for September as Sickle Cell Disease Awareness Month (H. Res. 1495/S. Res. 861)

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Social Security Administration (SSA)

Medicaid program reforms, including telemedicine and prior authorization issues Section 340B Drug Pricing program, including H.R. 5378 (Lower Costs, More Transparency Act), Section 202 Drug pricing reforms generally Juvenile mental and behavioral health legislation generally "Food as medicine" nutrition programs generally Advanced Research Projects Agency-Health program generally H.R. 3884 and S. 1852 (Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of2023), all provisions H.R. 3391 (Gabriella Miller Kids First Research Act 2.0), all provisions H.R. 3887 (Children's Hospital GME Support Reauthorization Act of2023), all provisions Medicare "site neutral" payment policy generally, including H.R. 5378 (Lower Costs, More Transparency Act), Section 203 Pediatric cancer research generally Pediatric access to cell and gene therapies generally H.R. 4758 (Accelerating Kids' Access to Care Act), all provisions H.R. 7213 (Autism Collaboration, Accountability, Research, Education, and Support Act of2024), all provisions H.R. 8260 and S. 4350 (Hospital Inpatient Services Modernization Act), all provisions Pediatric organ procurement and transplant policies generally Violence prevention programs generally

Client expense: $130,000 · Firm income: Not reported

Implementation of the No Surprises Act Blood and plasma safety and awareness Bleeding disorders awareness Issues related to plasma donation in border states Issues related to access to residential substance use disorder and mental health facilities for individuals with bleeding disorders Sickle Cell Care Expansion Act (H.R. 3100/S.1423) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 (H.R. 3884/S. 1852) Menstrual Equity for All Act (H.R. 3646) Securing Equal Access to Research, Care, and Health (SEARCH) Act Creating Hope Reauthorization Act of 2024 (HR 7384)

Client expense: Not reported · Firm income: $50,000

Government targets: Consumer Financial Protection Bureau (CFPB), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Sickle Cell Care Expansion Act (H.R. 3100/S.1423) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 (H.R. 3884/S. 1852) Sickle Cell Disease Treatment Centers Act (not yet introduced) Policies related to the social security disability programs, including letter to SSA seeking the review of the the disability criteria for sickle cell disease

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Social Security Administration (SSA)

Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic disease and disorders Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423/H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039/H.R. 6301) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages House discussion Draft of Stop Drug Shortages Act Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297) Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746) Sickle Cell Disease Comprehensive Care Act (H.R. 7432) H.Res. 1180, re: diversity, equity and inclusion in medical education

Client expense: $30,000 · Firm income: Not reported

H.R.6664 - Innovation in Pediatric Drugs Act of 2023 H.R.7384 - Creating Hope Reauthorization Act of 2024 H.Res.1307 - Expressing support for the designation of June 20, 2024, as "World FSHD Day". H.R. 7432, Sickle Cell Disease Comprehensive Care Act H.R. 7384, Creating Hope Reauthorization Act of 2024 S. 652, Safe Step Act H.R.1092, Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023 S. 1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 H.R. 830/S. 1375, HELP Copays Act H.R. 883/S. 320, Stop the Wait Act of 2023 H.R. 4758/S.2372, Accelerating Kids Access to Care Act H.R. 6094, Providing Realistic Opportunity To Equal and Comparable Treatment for (PROTECT) Rare Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

-Access to Therapeutic Apheresis, generally. -Sickle Cell Disease issues, generally; S.1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. -Blood collection issues, generally. -Medical device sterilization. -ARPA-H, cell collections issues, generally. -H.R.7432, The Sickle Cell Disease Comprehensive Care Act.

Client expense: $130,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Implementation of the No Surprises Act Blood and plasma safety and awareness Bleeding disorders awareness Issues related to plasma donation in border states Issues related to access to residential substance use disorder and mental health facilities for individuals with bleeding disorders Sickle Cell Care Expansion Act (H.R. 3100/S.1423) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 (H.R. 3884/S. 1852) Menstrual Equity for All Act (H.R. 3646)

Client expense: Not reported · Firm income: $50,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE

Sickle Cell Care Expansion Act (H.R. 3100/S.1423) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 (H.R. 3884/S. 1852) Sickle Cell Disease Treatment Centers Act (not yet introduced) Policies related to the social security disability programs, including letter to SSA seeking the review of the the disability criteria for sickle cell disease

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Social Security Administration (SSA)

-Access to Therapeutic Apheresis, generally. -Sickle Cell Disease issues, generally; S.1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. -Blood collection issues, generally. -Medical device sterilization. -ARPA-H, cell collections issues, generally.

Client expense: $120,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office

Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic disease and disorders Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423/H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039/H.R. 6301) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages House discussion Draft of Stop Drug Shortages Act Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297) Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746) Sickle Cell Disease Comprehensive Care Act (H.R. 7432)

Client expense: $30,000 · Firm income: Not reported

Sickle Cell Care Expansion Act (H.R. 3100/S.1423) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 (H.R. 3884/S. 1852) Sickle Cell Disease Treatment Centers Act (not yet introduced) H.Res. 692, Expressing support for the designation of September 2023 as Sickle Cell Disease Awareness Month S.Res., Expressing support for the designation of September 2023 as Sickle Cell Disease Awareness Month Congressional recognition of the Sickle Cell Disease Associations 50th Anniversary Comments in response to HHS/OCR Disability NPRM, RIN 0945-AA15

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Implementation of the No Surprises Act Blood and plasma safety and awareness Bleeding disorders awareness Issues related to plasma donation in border states Issues related to access to residential substance use disorder and mental health facilities for individuals with bleeding disorders Sickle Cell Care Expansion Act (H.R. 3100/S.1423) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 (H.R. 3884/S. 1852) Menstrual Equity for All Act (H.R. 3646) Letter RE: House Budget Committees Health Care Task Force Request for Information on containing health care costs

Client expense: Not reported · Firm income: $50,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE

Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic disease and disorders Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423/H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039/H.R. 6301) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages House discussion Draft of Stop Drug Shortages Act Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297) Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746)

Client expense: $30,000 · Firm income: Not reported

-Access to Therapeutic Apheresis, generally. -Sickle Cell Disease issues, generally; S.1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. -Blood collection issues, generally. -Medical device sterilization.

Client expense: $200,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Implementation of the No Surprises Act Blood and plasma safety and awareness Bleeding disorders awareness Issues related to plasma donation in border states Issues related to access to residential substance use disorder and mental health facilities for individuals with bleeding disorders Sickle Cell Care Expansion Act (H.R. 3100/S.1423) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 (H.R. 3884/S. 1852) Menstrual Equity for All Act (H.R. 3646) Medical Debt RFI

Client expense: Not reported · Firm income: $50,000

Government targets: Consumer Financial Protection Bureau (CFPB), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Sickle Cell Care Expansion Act (H.R. 3100/S.1423) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 (H.R. 3884/S. 1852) Sickle Cell Disease Treatment Centers Act (not yet introduced) H.Res. 692, Expressing support for the designation of September 2023 as Sickle Cell Disease Awareness Month S.Res., Expressing support for the designation of September 2023 as Sickle Cell Disease Awareness Month

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

-Access to Therapeutic Apheresis, generally. -Sickle Cell Disease issues, generally; S.1852, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023. -Blood collection issues, generally. -Medical device sterilization.

Client expense: $160,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic disease and disorders Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423 / H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages House discussion Draft of Stop Drug Shortages Act

Client expense: $30,000 · Firm income: Not reported

Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic disease and disorders Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423 / H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages

Client expense: $30,000 · Firm income: Not reported